Association of various insulin resistance surrogate indices with aging acceleration and future risk of cardiovascular disease in individuals with cardiovascular-kidney-metabolic syndrome stages 0–3: insights from China Health and Retirement Longitudinal Study (CHARLS) 2011–2020 data

Cardiovasc DiabetolPublished Prospective cohort study

Authors' conclusion

Multiple IR surrogate indices independently predict cardiovascular disease in CKM stages 0-3, with biological aging acceleration mediating this association. Integrating these measures into risk stratification could enable early identification and targeted intervention for high-risk individuals.

Study context

Population
Participants with cardiovascular-kidney-metabolic (CKM) syndrome stages 0–3, China Health and Retirement Longitudinal Study (CHARLS)
Participants
6,318 participants
Exposure
12 insulin resistance (IR) surrogate indices in relation to incident cardiovascular disease (CVD)
Outcome
New-onset CVD
Methodological detailsmultivariable-adjusted logistic regression, restricted cubic splines, quantile-based models, mediation analyses
  • Multivariable-adjusted logistic regression
  • Restricted cubic splines
  • Quantile-based models
  • Mediation analyses

Main finding

As reported in the abstract

Developed new-onset CVD
1231 (19.5%)
All IR surrogates significantly associated with CVD risk: TyG-derived indices, METS-IR, CTI and TG/HDL-C positive; eGDR inverse
all P-trend < 0.05

Observational data: associations, not effects.

Further findings

Effect modification

Significant modification by biological ageing acceleration, gender and CKM stage

Mediation by biological aging acceleration

Proportion of TyG-ABSI–CVD association mediated
14.9-16.4%
Proportion of other IR–CVD relationships mediated
1.3-4.2%

Original publication

Association of various insulin resistance surrogate indices with aging acceleration and future risk of cardiovascular disease in individuals with cardiovascular-kidney-metabolic syndrome stages 0–3: insights from CHARLS 2011–2020 data. Cardiovasc Diabetol. Published 4 February 2026. doi:10.1186/s12933-026-03084-5

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.